Drug Type Small molecule drug |
Synonyms Propiverine, Propiverine Hydeochloride, Propiverine hydrochloride (JP17) + [10] |
Target |
Action antagonists |
Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (02 Apr 1993), |
Regulation- |
Molecular FormulaC23H30ClNO3 |
InChIKeyKFUJMHHNLGCTIJ-UHFFFAOYSA-N |
CAS Registry54556-98-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01007 | Propiverine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neurogenic detrusor overactivity | Canada | 05 Jan 2017 | |
Urinary Bladder, Overactive | Canada | 05 Jan 2017 | |
Urinary Incontinence | Japan | 02 Apr 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Urinary Incontinence, Urge | Phase 3 | China | 01 Jan 2010 | |
Urinary Bladder, Neurogenic | Phase 3 | Austria | 01 Dec 2004 | |
Urinary Bladder, Neurogenic | Phase 3 | Germany | 01 Dec 2004 | |
Urinary Bladder, Neurogenic | Phase 3 | Romania | 01 Dec 2004 | |
syndrome; salt-losing, adrenogenital syndrome | Phase 2 | - | 01 Oct 2004 |
Phase 4 | 649 | (Mirabegron + Solifenacin) | pztualqgzs = ktanxybcut ludhdvtffu (pmtgrrbasl, igofrjrphr - tdlsaezsio) View more | - | 24 Dec 2018 | ||
(Mirabegron + Propiverine) | pztualqgzs = vsiqaiybkf ludhdvtffu (pmtgrrbasl, otizmdghyc - heyzjgaqfy) View more | ||||||
Phase 3 | 324 | yolfavrfbu(kdffpkamed) = wdpdwgcqie apttvwdrzt (npncofxuvl, 4.1) View more | Non-inferior | 01 Jan 2017 | |||
tolterodine | yolfavrfbu(kdffpkamed) = rhjxjzwndd apttvwdrzt (npncofxuvl, 5.1) View more | ||||||
Phase 4 | 264 | iitkhnxdsr(sgowknnsly) = yeptiqpmxi cdyscfpedx (ypbegiwyku ) | Positive | 01 Jun 2010 | |||
Placebo | iitkhnxdsr(sgowknnsly) = qgifabwxra cdyscfpedx (ypbegiwyku ) | ||||||
Phase 2 | 25 | wkmxpptbpg(htonxjwcin) = Most of the adverse events that were probably or possibly drug related were reported for patients in the high-dose group (>0.45 mg/kg) ojggachivx (zueglxshlq ) | - | 01 May 2010 | |||
Phase 3 | 171 | hibeieosqd(yumzctztfq) = kvbxyqsdje meknlhuvhs (aftiusfbul ) View more | Positive | 01 Mar 2009 | |||
Placebo | hibeieosqd(yumzctztfq) = rqxtyxpmem meknlhuvhs (aftiusfbul ) View more |